$TWST

Finn Patrick John sold $563K of TWST

Finn Patrick John (President and COO) sold 4,046 shares of Twist Bioscience Corp (TWST) at $139.07 ($0.56M total) on 2026-08-21.

Original reporting
SEC EDGAR · Finn Patrick John
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which may be interpreted as a lack of confidence, but the amount is small.

02

Market read

A modest insider sale by a senior officer; limited immediate market impact.

03

What to watch

No 10b5-1 plan was used; the timing may be unrelated to company fundamentals.

Relevance 5/10Novelty 4/10Timing: filing reported on Aug 25, 2026 (recent)

Background

Form 4 filings disclose insider trades; investors monitor them for potential signals.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

President and COO Finn Patrick John sold 4,046 shares for $562,661, reducing his stake to 210,802 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size (~$0.56M) is modest relative to market cap, but the insider is a senior officer, which can influence sentiment.

Market effects

Minimal impact on biotech sector; only a single insider transaction.

None

None

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Finn Patrick John

    President and COO of Twist Bioscience

  • Twist Bioscience Corp

    Biotech company listed on NASDAQ

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.